<DOC>
	<DOC>NCT02045719</DOC>
	<brief_summary>Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Patients and methods: This prospective phase II study will assess the effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals with advanced solid tumors, with no further therapeutic options and with at least 2 months life expectancy. In addition, several biochemical and inflammatory parameters will be analyzed.</brief_summary>
	<brief_title>Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>individuals with advanced solid tumors, with no further therapeutic options and with at least 2 moths life expectancy individuals 18 years of age and older creatinine levels up to twice the upper limit of normal (ULN) alanine (ALT) and aspartate (ASP) transaminase levels up to twice the ULN and direct bilirubin (DB) levels up to 1.5 times the ULN in cases with preexisting liver disease, the ALT, ASP and DB levels could be up to 2.5 times the ULN pregnant and breastfeeding women individuals using chemotherapy or other tumortargeting antineoplastic treatments, except for antalgic radiotherapy severe kidney or liver failure known hypersensitiveness to the components of the medication used past history of emotional disorders that could interfere with the data collection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>cat´s claw</keyword>
	<keyword>uncaria tomentosa</keyword>
	<keyword>quality of life</keyword>
	<keyword>no further therapeutic options</keyword>
</DOC>